1 BTC
=
- USD
Innoviva, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Innoviva, Inc. Common Stock
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Market Statistics
Trading Metrics
How to Buy INVA
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy INVA
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesThe article examines three small-cap stocks with low P/E ratios that may offer value opportunities. Innoviva Inc. (INVA) is a biotech company with a diversified business model including royalties and strategic investments, with analysts projecting a 50% upside despite a projected 2026 earnings decline. Wendy's (WEN) faces consumer headwinds but is controlling costs and offers an 8%+ dividend yield, potentially attractive if economic conditions improve. Nabors Industries (NBR) is a momentum play in oil and gas drilling services that has benefited from rising oil prices, though upside from current levels is limited.
The global tetracyclines market is experiencing steady growth at a CAGR of 5.23%, driven by broad-spectrum efficacy, cost-effectiveness, and expanding applications in respiratory infections, dermatology, and sexual health. Doxycycline dominates with 46.1% market share, while oral formulations lead with 64.0% share. Key growth drivers include rising antibiotic demand in veterinary and aquaculture sectors, emerging clinical applications like Doxy-PEP, and robust supply chains from China and India.
Two biotech companies are highlighted as standout investments for 2026. Axsome Therapeutics has strong late-stage pipeline developments with FDA acceptance of supplemental applications for AXS-05 in Alzheimer's agitation treatment and support for AXS-12 for narcolepsy, with 19 of 20 analysts rating it a Buy and targeting 8% upside. Innoviva received FDA approval for Nuzolvence, a first-in-class oral antibiotic for gonorrhea with significant market potential, and has shown strong financial performance with analyst consensus price target nearly double current trading levels.
Innoviva reported Q2 2025 earnings with $0.77 EPS and $100.3 million revenue, exceeding analyst expectations. Specialty therapeutics sales increased 54% year-over-year, driven by new product launches like GIAPREZA and ZEVTERA, while operating income declined due to increased R&D expenses.
Basilea Pharmaceutica Ltd has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, Inc. for the commercialization of Basilea's hospital anti-MRSA antibiotic Zevtera® (ceftobiprole) in the United States.